News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
623,875 Results
Type
Article (24342)
Company Profile (620)
Press Release (598908)
Multimedia
Podcasts (212)
Webinars (23)
Section
Business (198493)
Career Advice (1563)
Deals (31257)
Drug Delivery (145)
Drug Development (73014)
Employer Resources (89)
FDA (13699)
Job Trends (11580)
News (295701)
Policy (24582)
Tag
2025 Best Places to Work (25)
2026 Best Places to Work (39)
2027 BioCapital Standard (5)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (12)
2027 Biotech Beach Digital (1)
2027 Biotech Beach Standard (6)
2027 Genetown Elite (2)
2027 Genetown Standard (6)
2027 NextGen (10)
2027 Pharm Country Digital (4)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (5)
40 Under 40 (3)
Academia (1434)
Academic (1)
Accelerated approval (66)
ADA (52)
Adcomms (27)
Allergies (195)
Alliances (39569)
ALS (253)
Alzheimer's disease (1638)
Antibody-drug conjugate (ADC) (692)
Approvals (14461)
Artificial intelligence (887)
ASCO (309)
Autoimmune disease (485)
Automation (71)
Bankruptcy (319)
Belgium (37)
Best Places to Work (9258)
BIO (70)
Biologics (109)
BIOSECURE Act (16)
Biosimilars (245)
BioSpace Insights (193)
Biotechnology (326)
Bispecific (57)
Bladder cancer (240)
Brain cancer (91)
Breast cancer (909)
Cancer (7279)
Cardiovascular disease (609)
Career advice (1264)
Career pathing (36)
CAR-T (372)
CDC (35)
CDMO (153)
Celiac Disease (7)
Cell-line development (2)
Cell therapy (1031)
Cervical cancer (60)
Clinical research (67360)
Collaboration (2441)
Commercialization (68)
Company closure (8)
Compensation (1885)
Complete response letters (100)
COVID-19 (1748)
CRISPR (130)
CRO (6)
C-suite (1399)
Cystic fibrosis (150)
Data (10498)
Decentralized trials (3)
Denatured (78)
Depression (195)
Dermatology (199)
Diabetes (761)
Diagnostics (5955)
Digital health (61)
Diversity (12)
Diversity, equity & inclusion (19)
Drug discovery (446)
Drug pricing (132)
Drug shortages (23)
Duchenne muscular dystrophy (348)
Earnings (89667)
Editorial (51)
Employer branding (13)
Employer resources (82)
ESMO (408)
Events (109645)
Executive appointments (1189)
Eye disease (27)
FDA (18354)
Fibrodysplasia Ossificans Progressiva (16)
Fragile X (6)
Friedreich's ataxia (28)
Frontotemporal dementia (39)
Funding (1985)
Gene editing (270)
Generative AI (84)
Gene therapy (800)
GLP-1 (1063)
Government (2570)
Grass and pollen (7)
Guidances (424)
Healthcare (13823)
Hematology (208)
HIV (114)
Huntington's disease (84)
Idiopathic pulmonary fibrosis (16)
IgA nephropathy (149)
Immunology and inflammation (375)
Immuno-oncology (154)
Indications (287)
Infectious disease (2142)
Inflammatory bowel disease (240)
Inflation Reduction Act (13)
Influenza (144)
Intellectual property (355)
Interviews (282)
IPO (15297)
IRA (41)
Job creations (2726)
Job search strategy (1070)
JPM (46)
Kidney cancer (29)
Kidney disease (179)
Labor market (106)
Layoffs (403)
Leadership (43)
Legal (6206)
Licensing (124)
Liver cancer (103)
Longevity (50)
Lung cancer (1019)
Lung diease (24)
Lymphoma (528)
Machine learning (67)
Management (28)
Manufacturing (1259)
Marketing (38)
MASH (243)
Medical affairs (5)
Medical device (11452)
Medtech (11749)
Mergers & acquisitions (17367)
Metabolic disorders (1862)
Middle East (2)
mRNA (213)
Multiple sclerosis (241)
Multispecific (6)
NASH (20)
Netherlands (35)
Neurodegenerative disease (574)
Neuropsychiatric disorders (131)
Neuroscience (3565)
Neurotech (4)
NextGen: Class of 2026 (4664)
Non-profit (2672)
Now hiring (50)
Obesity (842)
Opinion (229)
Ovarian cancer (273)
Pain (312)
Pancreatic cancer (426)
Parkinson's disease (415)
Partnered (41)
Patents (708)
Patient advocacy (5)
Patient recruitment (864)
Patient selection (104)
Peanut (67)
People (48019)
Peptides (37)
Pharmaceutical (79)
Pharmacy benefit managers (29)
Phase 1 (20225)
Phase 2 (29306)
Phase 3 (22977)
Pipeline (13672)
Policy (246)
Postmarket research (2233)
Preclinical (8333)
Press Release (47)
Prostate cancer (371)
Psychedelics (85)
Radioligand (3)
Radiopharmaceuticals (365)
Rare diseases (1383)
Real estate (4029)
Recruiting (36)
Regenerative medicine (36)
Regulatory (22178)
Reports (70)
Research institute (1412)
Resumes & cover letters (289)
Rett syndrome (58)
RNA editing (33)
RSV (85)
Saudi Arabia (1)
Schizophrenia (212)
Series A (330)
Series B (232)
Service/supplier (16)
Sickle cell disease (135)
Special edition (35)
Spinal muscular atrophy (175)
Sponsored (42)
Startups (2729)
State (1)
Stem cells (8)
Stomach cancer (20)
Substance use disorders (22)
Supply chain (134)
Switzerland (20)
Tariffs (61)
Tax incentives (2)
The Weekly (133)
Vaccines (992)
Venture capital (146)
Weight loss (537)
Wet AMD (6)
Women's health (173)
Women in leadership (1)
Worklife (13)
Date
Today (178)
Last 7 days (852)
Last 30 days (3816)
Last 365 days (30197)
2026 (27475)
2025 (29217)
2024 (32233)
2023 (34094)
2022 (43089)
2021 (46217)
2020 (42868)
2019 (33208)
2018 (25053)
2017 (25908)
2016 (24448)
2015 (30608)
2014 (26457)
2013 (22079)
2012 (24088)
2011 (24329)
2010 (23389)
Location
Africa (572)
Alabama (110)
Alaska (5)
Arizona (401)
Arkansas (15)
Asia (32408)
Australia (5295)
California (16499)
Canada (4378)
China (1714)
Colorado (705)
Connecticut (712)
Delaware (498)
Europe (62661)
Florida (2423)
Georgia (510)
Hawaii (5)
Idaho (52)
Illinois (1341)
India (119)
Indiana (689)
Iowa (36)
Japan (757)
Kansas (139)
Kentucky (55)
Louisiana (64)
Maine (75)
Maryland (1836)
Massachusetts (11690)
Michigan (403)
Minnesota (845)
Mississippi (8)
Missouri (155)
Montana (34)
Nebraska (19)
Nevada (199)
New Hampshire (81)
New Jersey (4290)
New Mexico (31)
New York (4219)
North Carolina (1970)
North Dakota (11)
Northern California (8477)
Ohio (468)
Oklahoma (27)
Oregon (36)
Pennsylvania (3097)
Puerto Rico (35)
Rhode Island (54)
South America (831)
South Carolina (98)
South Dakota (1)
Southern California (6609)
Tennessee (228)
Texas (2678)
United States (56902)
Utah (489)
Vermont (1)
Virginia (365)
Washington D.C. (69)
Washington State (1301)
West Virginia (4)
Wisconsin (176)
Wyoming (2)
623,875 Results for "ev3 inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
R3 Vascular Appoints Lisa Wipperman Heine to its Board of Directors
September 21, 2026
·
3 min read
Press Releases
Imperative Care Announces Two New Board of Directors Appointments
November 10, 2026
·
3 min read
BioForest
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
Astellas Pharma Inc. and Seagen Inc. announced results from the Phase 3 EV-302 clinical trial for PADCEV® in combination with KEYTRUDA® versus chemotherapy.
October 22, 2023
·
27 min read
Drug Development
PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial
Astellas Pharma Inc. and Seagen Inc. announced positive topline results from the Phase 3 EV-302 clinical trial for PADCEV® in combination with KEYTRUDA® versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer, a form of bladder cancer that has spread to surrounding organs or muscles, or other parts of the body.
September 22, 2023
·
24 min read
Drug Development
Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
Merck, known as MSD outside of the United States and Canada, announced positive topline results from the Phase 3 KEYNOTE-A39 trial, which was conducted in collaboration with Seagen and Astellas, evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Padcev versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma.
September 22, 2023
·
47 min read
Press Releases
Eradivir Doses First Influenza Patient With EV25 in Bangladesh Study
July 7, 2026
·
3 min read
Business
KIYATEC Assay Hits the Mark in Study to Predict Patient Response to First Line Ovarian Cancer Drugs
Company’s Ovarian Assay is the First in a Series of Planned Indications Using EV3D Technology Platform Optimized for Solid Tumors
August 1, 2019
·
3 min read
Press Releases
AtaCor Medical Announces First Patient Treated Globally in its ALARION-EV Pivotal Trial
July 7, 2026
·
3 min read
Press Releases
Lifeloc Reports Second Quarter 2026 Results
August 14, 2026
·
11 min read
Job Trends
LEGO® Education and FIRST® Inspire STEAM Learning with New Architecture-Themed LEGO sets for 2019-2020 FIRST® LEGO® League Season
New LEGO® Education SPIKE™ Prime and new SPIKE™ Prime Expansion Set can now be used in FIRST LEGO League along with LEGO® MINDSTORMS® Education EV3.
April 17, 2019
·
4 min read
1 of 62,388
Next